Machine Learning and Gene Editing at the Helm of a Societal Evolution
RAND Health Quarterly, 2024; 11(2):5
RAND Health Quarterly, 2024; 11(2):5
RAND Health Quarterly is an online-only journal dedicated to showcasing the breadth of health research and policy analysis conducted RAND-wide.
More in this issueThe integration of artificial intelligence (AI) and biotechnology, whilst in its infancy, presents significant opportunities and risks, and proactive policy is needed to manage these emerging technologies. Whilst AI continues to have significant and broad impact, its relevance and complexity magnify when integrated with other emerging technologies. The confluence of Machine Learning (ML), a subset of AI, with gene editing (GE) in particular can foster substantial benefits as well as daunting risks that range from ethics to national security. These complex technologies have implications for multiple sectors, ranging from agriculture and medicine to economic competition and national security. Consideration of technology advancements and policies in different geographic regions, and involvement of multiple organisations further confound this complexity. As the impact of ML and GE expands, forward looking policy is needed to mitigate risks and leverage opportunities. Thus, this study explores the technological and policy implications of the intersection of ML and GE, with a focus on the United States (US), the United Kingdom (UK), China, and the European Union (EU). Analysis of technical and policy developments over time and an assessment of their current state have informed policy recommendations that can help manage beneficial use of technology advancements and their convergence, which can be applied to other sectors. This study is intended for policymakers to prompt reflection on how to best approach the convergence of the two technologies. Technical practitioners may also find it valuable as a resource to consider the type of information and policy stakeholders engage with.
As the impact of machine learning (ML) and gene editing (GE) expands, forward looking policy is needed to mitigate risks and leverage opportunities. The two technologies have increasing significance, the complexity of which magnifies when they integrate. Consideration of technology advancements and policies in different geographic regions, and involvement of multiple organisations, further confound this complexity. Thus, this study explores the technological and policy implications of the intersection of ML and GE, with a focus on the United States (US), the United Kingdom (UK), China and the European Union (EU). Analysis of technical and policy developments over time and an assessment of their current state have informed policy recommendations that can help manage beneficial use of technologies and their convergence. The proposed approach can be applied to a variety of technologies and sectors. This study is intended for policymakers to prompt reflection and consideration of how to approach the convergence of the two technologies most effectively. Technical experts and practitioners may also find it valuable as a resource when considering the type of information and policy stakeholders to engage with on technological development.
The integration of artificial intelligence (AI) and biotechnology, while in its infancy, presents significant opportunities and risks, and proactive policy is needed to manage these emerging technologies. While AI continues to have significant and broad impact, its relevance and complexity magnify when integrated with other emerging technologies. The confluence of AI with GE in particular can foster substantial benefits as well as daunting risks that range from lack of ethical considerations to national security. These complex technologies have implications for multiple sectors, ranging from agriculture and medicine to economic competition and national security. And this complexity expands with the number of organisations, government departments and countries involved in collaboration and/or competition.
Application of ML (as one aspect of AI) to GE and its underpinning bioinformatics platforms will catapult the revolutionary potential of GE from “hypothetical” to imminent. This poses specific risks like potential weaponisation and bioterrorism and opportunities like improved health and wellbeing. Given the pace of technology advancement and convergence, there is an impetus to track and assess advanced technologies while increasing the focus on policy development and societal debate. This combined field has not yet been adequately studied from a policy perspective.
It is critical for policymakers to take stock of advancements and assess where the combined technology could progress. Furthermore, the public requires improved understanding of the state of the art of ML and GE capabilities to comprehend societal implications and to contribute to policy discussions. However, the policy frameworks and parameters that exist today may no longer be fit for purpose.
Our study entailed a landscape analysis which led to a futures assessment to identify prevalent risks and opportunities. We explored the current state of ML and GE technologies and policies, used historical analysis to project potential future risks and opportunities, and surfaced risks and opportunities of technology alongside potential policy interventions with a future focussed table-top exercise.
The landscape assessment consisted of software-assisted horizon scanning to summarise the state of the art of ML and GE capabilities as well as the integrated applications of these capabilities. We categorised these capabilities and applications based on their technology readiness levels (TRLs), their potential impact and the current barriers to further progress. We complemented this analysis with a desk-based review of the key policies that predate and/or follow GE and ML advancement, to assess their interplay and connectedness. We supplemented this assessment with interviews of subject matter experts on risks and opportunities. This analysis resulted in timelines of primary policy and technical developments across the United States, the United Kingdom, China and the European Union. These timelines were in turn used to extract past trends, extrapolate potential future trends, and compare policies and technologies between regions.
The futures assessment built on outputs from the landscape assessment and provided a deeper analysis of international relationships and more extensive policy actions. This led to the identification of primary drivers of change with regards to the convergence of these technologies, based on proposed future scenarios looking towards 2045. The scenarios were used in a discursive seminar game to develop potential policy actions to minimise harm and maximise opportunities across the United States, the United Kingdom, China and the European Union.
The figure shows two overlapped circles.
The left circle is labeled Gene editing technologies. It contains the following items: Embryo model system, Precision editing, Knowledge bases and 'omics' libraries, and Genome-Wide Association Studies.
The right circle is labeled Artificial intelligence technologies. It contains the following items: Deep learning models, Large language models, and Artificial general intelligence.
The overlapping area in the middle contains the following items: Genome engineering, Predictive genome-phenome, and Protein folding and modeling. An area below the circles that expands from the center overlapping area is labeled Unlocked capabilities and contains the following items (each with an illustrative icon): Predictive power (with a silhouette of a head that contains a gear that is sorting items), Understanding of molecular models and systems (with a magnifying glass), Amplification of scale and increased rapidity (with an unlabeled speedometer with the pointer in the upper range), Improved data utility (with an upwards graph in a gear), and Improved targeting (with an arrow in the center of a target).
This research was conducted by RAND Europe.
More in this issueRAND Health Quarterly is produced by the RAND Corporation. ISSN 2162-8254.
Explore RAND Health Quarterly articles on PubMed